SK Biopharmaceuticals (SK Biopharm) reports a sharp rise in third-quarter operating profit, driven by stronger U.S. sales of its oral anti-seizure medication. The company says operating profit increases 65.9% year-on-year to 116.3 billion won in the July–September period, while sales rise 34.8% to 258.4 billion won. It also reports net income falls 23.9% to 54.3 billion won.
SK Biopharm links the operating profit improvement to growth of Cenobamate, known as Xcopri in the United States, and to factors including exchange-rate-related adjustments. It says U.S. sales from the prescription drug total $156.8 million, up 29.9% from a year earlier, and that Cenobamate’s aggregate sales as of late September reach about 76% of the company’s upper-end annual revenue guidance of $580 million.
Across outlets, the coverage emphasis stays largely aligned on the profit jump and the role of U.S. seizure-drug sales. One outlet also adds a reference point versus market expectations, noting that operating profit exceeded an average estimate, while others focus more on the company-reported figures and the drug-driven explanation.